EDIT up +140% over last 3 days. Pullback expected here. Gene editing is a hot topic at the moment, but price is absolutely overextended for company with less than $100M revenue annually. Long term huge long potential. Short term, short biased.
Trade closed: target reached
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.